164 related articles for article (PubMed ID: 38447541)
1. Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma.
Heini AD; Bacher VU; Akhoundova D; Seipel K; Pabst T
Acta Haematol; 2024 Mar; ():. PubMed ID: 38447541
[TBL] [Abstract][Full Text] [Related]
2. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
[TBL] [Abstract][Full Text] [Related]
4. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
5. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
6. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
Shrestha A; Alzubi M; Alrawabdeh J; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Al Hadidi S
EJHaem; 2024 Jun; 5(3):554-559. PubMed ID: 38895072
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
8. Talquetamab: First Approval.
Keam SJ
Drugs; 2023 Oct; 83(15):1439-1445. PubMed ID: 37792138
[TBL] [Abstract][Full Text] [Related]
9. Talquetamab in multiple myeloma.
Liu L; Krishnan A
Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Chari A; Krishnan A; Rasche L; Ye JC; Garfall A; Popat R; Lipe B; Qin X; Campagna M; Masterson T; Tomlinson C; Hilder B; Tolbert J; Renaud T; Smit MD; Gray K; Kane C; Heuck C; van de Donk NWCJ
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38871558
[TBL] [Abstract][Full Text] [Related]
11. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Chari A; Askari E; Caers J; Costa LJ; Hilder BW; Krishnan A; Mateos MV; Minnema MC; Oriol A; Pillarisetti K; van de Donk NWCJ; Rodríguez-Otero P
Future Oncol; 2023 Sep; 19(27):1823-1840. PubMed ID: 37492991
[TBL] [Abstract][Full Text] [Related]
12. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
13. MonumenTAL Results for Talquetamab in Myeloma.
Cancer Discov; 2023 Feb; 13(2):250-251. PubMed ID: 36508587
[TBL] [Abstract][Full Text] [Related]
14. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab.
Lery M; Perrot A; Ortiz-Brugués A; Vigarios E; Anghel D; Bories P; Sibaud V
J Am Acad Dermatol; 2024 Feb; 90(2):376-377. PubMed ID: 37742842
[No Abstract] [Full Text] [Related]
15. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
Lipe BC; Renaud T
J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
17. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
Del Giudice ML; Galimberti S; Buda G
Cancer Immunol Immunother; 2023 Dec; 72(12):3931-3937. PubMed ID: 37924369
[TBL] [Abstract][Full Text] [Related]
18. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
19. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.
Kodama T; Kochi Y; Nakai W; Mizuno H; Baba T; Habu K; Sawada N; Tsunoda H; Shima T; Miyawaki K; Kikushige Y; Mori Y; Miyamoto T; Maeda T; Akashi K
Mol Cancer Ther; 2019 Sep; 18(9):1555-1564. PubMed ID: 31270154
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
